Merit Medical SystemsMMSI
MMSI
About: Merit Medical Systems Inc is a medical equipment company that develops and manufactures products for use in interventional cardiology, radiology, and endoscopy procedures. The firm reports two segments which are Cardiovascular and Endoscopy. The majority of the revenue is earned from the Cardiovascular segment. The United States generates the majority of the revenue.
Employees: 6,950
0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
12,410% more call options, than puts
Call options by funds: $89.1M | Put options by funds: $712K
183% more first-time investments, than exits
New positions opened: 82 | Existing positions closed: 29
17% more funds holding
Funds holding: 319 [Q2] → 372 (+53) [Q3]
12% more repeat investments, than reductions
Existing positions increased: 128 | Existing positions reduced: 114
10% more capital invested
Capital invested by funds: $5.31B [Q2] → $5.82B (+$508M) [Q3]
4.8% less ownership
Funds ownership: 106.35% [Q2] → 101.55% (-4.8%) [Q3]
67% less funds holding in top 10
Funds holding in top 10: 3 [Q2] → 1 (-2) [Q3]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$109
11%
upside
Avg. target
$116
18%
upside
High target
$127
29%
upside
5 analyst ratings
5 positive
100%
0 neutral
0%
0 negative
0%
Barrington Research Michael Petusky 38% 1-year accuracy 26 / 69 met price target | 16%upside $114 | Outperform Maintained | 23 Dec 2024 |
Wells Fargo Larry Biegelsen 51% 1-year accuracy 24 / 47 met price target | 22%upside $120 | Overweight Upgraded | 11 Dec 2024 |
Canaccord Genuity Jon Young 50% 1-year accuracy 3 / 6 met price target | 29%upside $127 | Buy Maintained | 9 Dec 2024 |
Needham Mike Matson 50% 1-year accuracy 59 / 117 met price target | 11%upside $109 | Buy Reiterated | 31 Oct 2024 |
Baird David Rescott 83% 1-year accuracy 10 / 12 met price target | 11%upside $109 | Outperform Maintained | 31 Oct 2024 |
Financial journalist opinion
Based on 7 articles about MMSI published over the past 30 days
Positive
Zacks Investment Research
3 days ago
Merit Medical Stock Rises Following FDA Nod for WRAPSODY Device
MMSI announces FDA approval for the WRAPSODY Cell-Impermeable Endoprosthesis.
Neutral
GlobeNewsWire
6 days ago
Merit Medical Announces FDA Approval of the WRAPSODY Cell-Impermeable Endoprosthesis
SOUTH JORDAN, Utah, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that the WRAPSODY® Cell-Impermeable Endoprosthesis has received premarket approval from the US Food and Drug Administration (FDA). With this approval, Merit can begin commercialization of the device in the USA in 2025.
Neutral
GlobeNewsWire
1 week ago
Merit Medical Announces Resignation of President, Joseph Wright
SOUTH JORDAN, Utah, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI) (“Merit” or the “Company”), a global leader of healthcare technology, today announced the resignation of its President, Joseph C. Wright, effective January 3, 2025.
Positive
Zacks Investment Research
1 week ago
Why Merit Medical (MMSI) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Neutral
Zacks Investment Research
1 week ago
Zacks Industry Outlook Becton, Dickinson, BD, McKesson, Cardinal Health and Merit Medical Systems
Becton, Dickinson, BD, McKesson, Cardinal Health and Merit Medical Systems have been highlighted in this Industry Outlook article.
Neutral
Zacks Investment Research
2 weeks ago
4 Stocks to Watch Amid Dental Supplies Industry Challenges
Here we discuss four stocks from the Dental Supplies industry that are likely to earn wealth for investors. These are BDX, MCK, CAH and MMSI.
Neutral
Zacks Investment Research
3 weeks ago
MMSI or WST: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Medical - Dental Supplies sector might want to consider either Merit Medical (MMSI) or West Pharmaceutical Services (WST). But which of these two stocks presents investors with the better value opportunity right now?
Neutral
Zacks Investment Research
4 weeks ago
MMSI Stock Down Despite Latest Positive Data From WRAPSODY WAVE Trial
The significant improvement in patency rates for AVG patients via Merit Medical's WRAPSODY device is expected to enhance patients' vascular access survival.
Neutral
GlobeNewsWire
1 month ago
Fundus Camera Market Global Forecasts and Company Analysis 2025-2033, Profiles of Carl Zeiss Medites, Topcon Medical Systems, Merit Medical Systems, NIDEK, and Revenio Group
Dublin, Nov. 25, 2024 (GLOBE NEWSWIRE) -- The "Fundus Camera Market Global Forecast Report by Product Type, End-User, Countries and Company Analysis 2025-2033" report has been added to ResearchAndMarkets.com's offering. The Fundus Camera market was valued at US$459.40 million in 2024 and is anticipated to hit US$665.85 million by 2033 from 2025 to 2033 with a compound annual growth rate of 4.21%. The primary reason for this growth stems from the demand for more developed diagnostics within the eyes, mainly because of retinal disorders that have been on the rise across the globe. A fundus camera is a medical imaging device specific in the application of ophthalmology to capture high resolution images of the internal eye, with emphasis on the retina, optic disc, and macula. It illuminates and photographs the retina through the pupil to provide critical details necessary for diagnostics and management procedures in various eye conditions. Fundus cameras thus play an instrumental role in detecting retinal disorders including diabetic retinopathy, glaucoma, age-related macular degeneration, and retinal detachment. These conditions often progress in a gradual manner but may go unnoticed until they start impairing vision seriously. In that case, early detection via the use of fundus photography will give time to intervene before more serious vision loss takes place. There are mydriatic, non-mydratic, and hybrid types available, and there are also handheld or portable types for easier access. Apart from diagnosis, follow up of disease progression and effectiveness of the treatment being provided makes fundus imaging a tool more essential in eye care. Growth Drivers for the Fundus Camera Market
Neutral
GlobeNewsWire
1 month ago
Merit Medical's WRAPSODY WAVE Trial Exceeds Performance Goals for Arteriovenous Graft (AVG) Patients
WRAPSODY achieves 82% target lesion primary patency at six months in the single-arm cohort of the US pivotal trial WRAPSODY achieves 82% target lesion primary patency at six months in the single-arm cohort of the US pivotal trial
Charts implemented using Lightweight Charts™